No blended recommendations
A label and a professional guideline may differ. A different formulation or indication may only appear to conflict. Read the complete stored source, its date, renal measure, population and qualifications. These new interpretations remain pending independent clinical review.
Find a review question
Use drug/source terms only, never patient identifiers. Filters are in the URL. No JavaScript is required. CSV includes all matches, not just this page.
279 matching checks; page 5 of 28.
Product and indication | Added v5.7
Prevention and combination HIV treatment have different renal wording?
Cabotegravir - APRETUDE intramuscular injection
APRETUDE and CABENUVA are not interchangeable products. HIV testing remains essential before each APRETUDE injection.
What to checkConfirm the product, indication and acute-infection testing. Do not infer a dialysis supplement from protein binding.
Related formulations / records - not interchangeable
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Product and indication | Added v5.7
Retain the increased-monitoring instruction in severe renal disease?
Cabotegravir / rilpivirine - CABENUVA intramuscular kit
CABENUVA specifies additional adverse-effect monitoring in severe impairment and ESRD. The RX retrieval failed; this addition is official-label content.
What to checkConfirm HIV-treatment eligibility and injection schedule; do not replace this instruction with APRETUDE wording.
Related formulations / records - not interchangeable
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Neonatal monitoring and product identity | Added v5.7
Observed trial concentrations are not a validated therapeutic range?
Caffeine citrate - CAFCIT oral solution and injection
The neonatal source calls for concentration monitoring without a clearance-band regimen.
What to checkConfirm citrate versus base expression and neonatal monitoring; no adult CrCl algorithm or invented target is supplied.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Stage and biochemical eligibility | Added v5.7
A CKD indication is not permission to treat every renal stage?
Calcifediol - RAYALDEE extended-release capsules
The selected RAYALDEE titration depends on stage and biochemical criteria, and excludes CKD stage 5 or dialysis.
What to checkKeep calcium, phosphorus, PTH and vitamin D requirements attached; do not substitute calcitriol.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Dated label and pharmacogenetic safety | Added v5.7
Current label renal wording and DPYD testing need a dated reading?
Capecitabine
The retrieved 2026 official labels state that a dosage below Cockcroft-Gault CrCl 30 is not established, whereas the older generic RX mirror calls this range contraindicated. Current labels also include pretreatment DPYD testing precautions.
What to checkUse the exact current product label and oncology protocol; do not interpret absence of an established dose as permission. Older eviQ comparisons were not rechecked in this pass.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
No adjustment and monitoring | Added v5.7
No adjustment in studied impairment is not protection from treatment-related renal injury?
Capivasertib - TRUQAP oral tablets
The source leaves severe impairment unstudied and separately warns about hyperglycemia, diarrhea and dehydration.
What to checkKeep renal follow-up and treatment-related complications separate from baseline renal dosing.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Renal measure and evidence gap | Added v5.7
Keep Cockcroft-Gault and the unstudied severe range explicit?
Capmatinib - TABRECTA oral tablets
The no-adjustment finding is limited to the selected Cockcroft-Gault mild/moderate renal range.
What to checkDo not convert an unstudied severe range into a dose or silently substitute indexed eGFR.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Formulation vehicle and availability | Added v5.7
The IV vehicle restriction must not be transferred to oral carbamazepine?
Carbamazepine - CARNEXIV intravenous injection
The selected IV source warns about cyclodextrin accumulation and generally avoids moderate or severe renal impairment. Current availability was not verified.
What to checkMatch route and vehicle; do not invent severity cutoffs or a reduced IV schedule to bypass the restriction.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Table integrity and renal measure | Added v5.8
Do not repair a damaged renal dose table by assumption?
Carboplatin - intravenous injection
The mirror has missing separators in its BSA-based renal bands. Its separately legible Calvert relationship uses GFR and produces a total mg dose.
What to checkKeep the malformed rows on hold. Confirm the oncology protocol, target exposure and renal-function method before using a dosing equation.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Indication measure and daily dose | Added v5.7
Total daily doses, indexed eGFR and metabolic indication must stay together?
Carglumic acid - CARBAGLU tablets for suspension
CARBAGLU has separate renal tables for NAGS deficiency and acute PA/MMA-associated hyperammonemia. The numbers are total daily doses, not doses per administration.
What to checkConfirm the indication, indexed eGFR, actual weight/BSA, dose splitting and rounding before prescribing; no ESRD dose is inferred.
Source-specific interpretation; independent clinician adjudication pending. No patient-specific action has been selected.
Before using a source
Confirm exact product and route, indication, age/weight, renal estimate and units, changing renal function, dialysis modality and timing, interacting medicines, monitoring, and the applicable institution's review. A successful page retrieval or a source-count badge establishes none of these on its own.
Clinician interpretation guideReturn to top